Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects


This clinical study is designed to evaluate the safety and tolerability of a single oral administration of a Metadoxine slow release formulation to subjects diagnosed as having ADHD. Study also assess cognitive effects of such drug administration.

Full Title of Study: “Efficacy Study of Metadoxine SR Formulation in ADHD Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2010

Detailed Description

Primary outcome measure is the safety and tolerability of study drug after a single dosing. Additional outcomes include commission error rate from the TOVA test. The result is measured as standard score in % compared to the values of the normal population. Exploratory outcome measures include: 1. TOVA measures like response time , variability, omissions etc. 2. Subtests from Wechsler: digit memory, digit-number signs etc


  • Drug: Extended Release Metadoxine
    • one oral 1400mg dose (2 tablets)

Arms, Groups and Cohorts

  • Experimental: Metadoxine SR
    • Metadoxine is a pyrolate salt of Pyridoxine

Clinical Trial Outcome Measures

Primary Measures

  • Safety and Tolerability
    • Time Frame: 24 hours after drug adminstration
    • Subjects were evaluated for general safety and tolerablity measures, including number of AEs and AEs related (possibly or likely) to study drug

Participating in This Clinical Trial

Inclusion Criteria

  • age 18-45 – diagnosed as ADHD Exclusion Criteria:

  • PDD patients – head injured patients – patients suffering from heart, lung, liver, kidney, intestinal, endocrine an neurological diseases and patients who are sensitive to vitamin B

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Alcobra Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Iris Manor, MD, Principal Investigator, Geha MC, Israel

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.